Skip to content
Four vintage microphones form columns supporting a detailed classical pediment against a solid red background, combining media and architecture themes.

Justice Alito Stays Ruling on Abortion Pill by Mail

Listen on your player of choice

Justice Samuel Alito allows medical companies to continue administering the abortion pill Mifepristone after the 5th Circuit Court of Appeals ordered for it to be dispensed only in person. Sarah Isgur and David French discuss the role of standing in judicial review and abortion access after Donald Trump’s presidency.

The Agenda:
–Court issues temporary order allowing access to abortion pill by mail
–The 5th Circuit is the outlier court
–Overturning Roe V. Wade didn’t end abortion
–Can Trump end Temporary Protected Status Program for Haitians and Syrians?
–What if this was all racially motivated?
–Justices appear mixed on whether geofence warrant violated the Fourth Amendment
–Listener questions!

Order Sarah’s book here.

Advisory Opinions is a production of The Dispatch, a digital media company covering politics, policy, and culture from a non-partisan, conservative perspective. To access all of The Dispatch’s offerings—including access to all of our articles, members-only newsletters, and bonus podcast episodes—click here. If you’d like to remove all ads from your podcast experience, consider becoming a premium Dispatch member by clicking here.

Want to see more of The Dispatch in Google search?

Add Us as a Preferred Source

Sarah Isgur is a senior editor at The Dispatch and is based in Texas. Prior to joining the company in 2019, she had worked in every branch of the federal government and on three presidential campaigns. She’s also an ABC News contributor and the New York Times bestselling author of Last Branch Standing, a deep dive into the inner workings of the Supreme Court. When Sarah is not hosting podcasts or writing newsletters, she’s probably sending uplifting stories about spiders to Jonah, who only pretends to love all animals.

David French is a columnist for the New York Times. He’s a former senior editor of The Dispatch. He’s the author most recently of Divided We Fall: America's Secession Threat and How to Restore Our Nation.

The podcast transcription below was generated using artificial intelligence and may include occasional errors or misspellings.

Music

You ready?

Music

I was born ready.

Sarah Isgur

[upbeat music] Welcome to Advisory Opinions. I'm Sarah Isgur. That's David French. We are going to start with the Fifth Circuit's decision on whether doctors can prescribe mifepristone, an abortion-inducing drug, without an in-person doctor's visit. Can they do it through the mail? The Supreme Court, with an administrative stay issued by Justice Alito, has put that ruling on hold, so doctors can still follow the FDA's guidance on sending those prescriptions without an in-person visit. We will then look at the two oral arguments from last week, one, removing temporary protected status for Haitians and Syrians by the Trump administration, and two, geofencing your phone's location data while you rob a bank. What exactly is required in that warrant? And finally, we'll get to some questions from you guys on David's top five list of cases, and look, maybe our takedown of Justice Holmes has been wrong this whole time. Plus, a rock that changed history. All this and more on Advisory Opinions. David, Monday morning, the Supreme Court stayed the Fifth Circuit's unanimous panel decision that would have stopped mifepristone from being prescribed without an in-person doctor's visit. Let's dive into this, but first, the Supreme Court stayed the Fifth Circuit. This is an interim docket decision. I will admit I was shocked that it came about 12 hours after I had predicted in my own household that we would get this exact outcome. So after the Fifth Circuit decided this case on Friday, the, uh, companies that manufacture mifepristone immediately asked the Supreme Court to stay the ruling. That, just from a procedural standpoint so people understand, each circuit is assigned a justice. The justice in charge of the Fifth Circuit is Justice Sam Alito. So David, from there, Justice Alito can decide to deal with this on his own, called an in chambers order, or he can send it to the full court. Here we have two in chambers orders from Justice Alito putting the Fifth Circuit's decision on hold for both companies that manufacture mifepristone. Uh, so let's just start with the Supreme Court a- part of this, David. Any thoughts, feelings on, you know, is this correct or something? [chuckles]

David French

I'm actually fascinated by this happening so quickly, and I'm, I, I want to explore your confidence on it, Sarah, because we have seen a mifepristone case at the Supreme Court recently, and this was a unanimous 2024 case holding that the plaintiffs lacked ch- Article III standing to challenge the FDA's actions. Um, and these were plaintiffs who were, uh, doctors who were, whether they were going to be dispensing mifepristone or dealing, really actually dealing with the effects of other people dispensing mifepristone, and there was no standing. So in this one, here you're running essentially back, trying to run a s- the same case on the merits back up through a different plaintiff. In this case, you've got a Louisiana plaintiff that they're trying to run this back with. And, and so the Fifth Circuit said unlike, you know, uh, the doctors, this is a distinguishable situation from the doctors, the state has standing, and there just wasn't sufficient work necess- the, the, the proper hoops weren't jumped through to approve mifepristone without in-person doctor visits. It was actually a really surprisingly brief opinion, Sarah. It wasn't, it wasn't that comprehensive an, of an opinion, and they stayed it, and it went back up to Samuel Alito. And I guess the question I have is where, why did you have confidence, Sarah? Was it the standing piece of it or the merits piece of it that gave you confidence that Justice Alito would s- or that it would be stayed?

Sarah Isgur

This is one of those rare all of the above cases. We had quite a few things happening in this case that made me incredibly confident, though again, I was 12 hours off. I thought by 9:30 last night, on Sunday night, that we would have this from the Supreme Court. Uh, it was 9:28, and I was like, "Woo, what's going on here?" But, you know, not to worry, by 11:00 AM we had it. So a few things. One, the district court found that the FDA had not, uh, cut square corners, if you will, in allowing for the, um, non-in-person prescriptions for mifepristone, but nevertheless stopped, uh, did not, like, have, you know, an injunction go into effect. So first of all, you have a disagreement between the district court and the circuit court of what the effects of that temporary ruling should be, and that's generally, like, pretty ripe for the Supreme Court to, like, step in first. Second,

Interactive transcripts are available to Premium members. Join to follow along with the audio.

Join Now

More We Think You’d Like

Loading